AI Resilience Report forRegulatory Affairs Managers

Right now, AI is mostly helping Regulatory Affairs Managers rather than replacing them. The biggest changes are in document writing and research. McKinsey reports that generative AI-assisted medical writing can cut clinical study report cycle time by about 40% ^[1], which lets managers spend more time on strategy and review instead of paperwork.

The RAPS Journal of Regulatory Affairs notes that new tools must work inside existing quality systems, where manufacturers are advised to set up cross-functional governance teams, run gap assessments, and integrate AI oversight into their evolving quality management systems, layering AI onto—not replacing—human judgment.

Regulators are also drawing clear lines. In a recent warning letter covered by RAPS, the FDA cited a cosmetics drug firm for "excessive reliance on artificial intelligence" to write specifications and procedures without proper human quality oversight ^[2]. And in January 2026, the EMA and FDA jointly released ten guiding principles emphasizing a human-centric approach and continuous oversight ^[3] across the drug-development lifecycle.

Adoption is moving steadily but carefully. Commercial gen-AI tools for drafting, intelligence monitoring, and submission review are widely available, and the cost savings are real. But several things slow things down: heavy legal accountability, strict rules like the EU AI Act, and the need for human judgment in audits, complaint handling, and clinical trial protocols.

BCG's 2026 analysis estimates that 50-55% of U.S. jobs will be reshaped—not eliminated—by AI over the next two to three years ^[4], with full substitution coming much more slowly. The Federal Reserve similarly finds no evidence yet of reduced job postings in industries with higher AI adoption ^[5]. For Regulatory Affairs Managers, the message is hopeful: AI will handle more drafting and data-crunching, but your judgment, ethics, and ability to communicate with regulators remain hard to automate—and increasingly valuable.